The General Meeting is Oasmia’s highest decision-making body, at which the shareholders exercise their voting rights.
At the Annual General Meeting (AGM), which must be held within six months of the end of the financial year, shareholders resolves on key issues, such as the adoption of income statements and balance sheets, appropriation of the company’s result, discharge from liability of members of the Board of Directors and the CEO, election of members of the Board of Directors and auditors and remuneration to the Board of Directors and the auditor.
No later than in conjunction with the publication of the third-quarter report, the date and place of the AGM is published on the company’s website. The notice of the AGM is published at the earliest six weeks, but no later than four weeks, before the date of the AGM.
In addition to the AGM, Extraordinary General Meetings may be convened when required.
Shareholders who are registered in Euroclear Sweden AB’s share register as of the record day and, by the date specified in the notice, have reported their intention to attend may participate and vote at the General Meeting, in person or by a representative.
Shareholders who wish to have a matter brought before the General Meeting must submit a written request to the Board of Directors. Normally, the request must be received by the Board of Directors no later than seven weeks prior to the General Meeting. Shareholders may submit their requests by e-mail to email@example.com or by ordinary mail to the following address:
Oasmia Pharmaceutical AB
Att: The Board of Directors
SE 752 28 Uppsala